Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term access study of berotralstat in hereditary angioedema
2024-511285-37-00Phase 4Authorised
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 4, open-label, single-arm trial of berotralstat in hereditary angioedema (HAE), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoints: Treatment-related TEAEs, Serious adverse events and 3 more. Planned start Jul 2024; status: authorised.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2024-511285-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511285-37-00.